Extraction vessels

Extraction vessels

We design and manufacture vessels for aqueous, oily or solvent-based plant extracts. Satisfying current hygiene standards, our systems are mainly used in the pharmaceutical and food industries. Filtrate, buffer and storage vessels can also be used.

Articles in the range Extraction vessels

Cosmetics industry Food industry Pharmaceutical

Extraction system

Pharmaceutical extraction system for the production of plant extracts. Conformity pursuant to PED 2014/68/EU Cat. 4/Module G, ATEX Directive 2014/34/EU and MD 2006/42/EU.
Torispherical head, with dome pressure cover in cylindrical wall. Base with rotatable closure and filter insert. The tanks are fitted with a platform, control device and weighing technology.
Equipment also includes:
  • Filter base/insert
  • Swivel catch
  • Temperature measuring equipment
  • O² measurement
  • Liquid level monitoring
  • Metaglas sight glass
  • LED sight glass lights
  • Rupture disc / safety valve
  • Product tubes
  • Sampling and outlet valve
  • CIP cleaning nozzle
  • ATEX design
  • Control cabinet in line with ATEX
Industry: Pharmaceutical
Product: Extraction, liquids
500l – 2.500l
Tank product chamber:
p = -1 / +4 bar,
t = -10 / +50 °C
Parts in contact with product 1.4404/1.4435 , with APZ 3.2/3.1 AD 2000, Ra <0.8µm

Dear Sir or Madam,
Dear Mr Weinert,

On April 30, 2021, we will open another site at Allergopharma GmbH & Co. KG in Reinbek to support COVID 19 vaccine production in the presence of Federal Minister Spahn and Minister President Günther. We would have been pleased to invite you to this opening.

Unfortunately, this was not possible due to the pandemic.
We would therefore like to take this opportunity to thank you for your extraordinary commitment to supplying equipment at short notice to support vaccine production. Allergopharma, as part of Dermapharm Holding SE, is now a further partner in the Europe-wide production network for the vaccine of BioNTech and Pfizer. This network now comprises more than a dozen important pharmaceutical manufacturers and suppliers. From now on, one of four production steps will take place in Reinbek: the vaccine formulation. This is where our mRNA active ingredient is combined with the lipids. A protective shell is created around the mRNA and the vaccine can reach its target in the body to induce the necessary immune response.

Your company has made a very important contribution to the global pandemic response with great know-how and under incredible time pressure. We would like to express our sincere thanks to you and your team! Without their commitment, the successful completion of the project would not have been possible.
We look forward to working with you in partnership in the future!

Dr. Hans-Georg Feldmeier – CEO Dermapharm SE
Dr. Sierk Poetting – CFO and COO BioNTech SE